Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;44(2):141-148.
doi: 10.1002/phar.2898. Epub 2023 Dec 16.

Evaluation of the safety and tolerability of intravenous undiluted levetiracetam at a pediatric institution

Lily Price  1 , Lisa Garrity  1 , Sarah Stiehl  1
Affiliations

Evaluation of the safety and tolerability of intravenous undiluted levetiracetam at a pediatric institution

Lily Price et al. Pharmacotherapy. 2024 Feb.

Abstract

Study objective: Recent studies suggest rapid administration of high-dose, undiluted levetiracetam is safe in adults; however, no information exists in pediatric patients. The purpose of this study was to evaluate the safety and tolerability of undiluted levetiracetam at a pediatric institution.

Design: Retrospective, single-center, cohort study.

Setting: Pediatric Academic Medical Center.

Patients: All patients who received high-dose >60 mg/kg (-10%) up to 4500 mg undiluted or diluted intravenous levetiracetam were included.

Intervention: Rapid intravenous administration of undiluted versus diluted levetiracetam.

Measurements and main results: A total of 776 levetiracetam doses were included, 358 doses administered and 418 doses wasted. The doses administered (61 undiluted and 297 diluted) accounted for a total of 252 patients (39 received undiluted, and 213 received diluted levetiracetam) (median [minimum-maximum range] age, 2 years [1 day to 32.7 years]; mean (standard deviation [SD]) weight, 20.1 kg [22.1 kg]). The incidence of hemodynamic disturbances and infusion-related reactions was not statistically significant between undiluted (24.6%) and diluted (26.3%) groups (p = 0.87). The median (interquartile range [IQR]) time difference between first-line antiseizure medication and levetiracetam administration in patients with status epilepticus was 18 min (10.5-30.5) in the undiluted group versus 36.5 min (21.8-67.3) in the diluted group (p < 0.01). Additionally, there was a significant amount of drug waste from dispensed but not administered doses of the diluted bag compared to undiluted vials (57.6% diluted vs. 18.7% undiluted, p < 0.001).

Conclusion: Undiluted levetiracetam was not associated with an increased incidence of adverse effects compared to diluted levetiracetam in high-doses, up to 4500 mg given over 5 min in pediatric patients.

Keywords: child; drug-related side effects and adverse reactions; levetiracetam; status epilepticus.

PubMed Disclaimer

References

REFERENCES

    1. Wylie T, Sandhu DS, Murr N. Status Epilepticus. StatPearls. StatPearls Publishing Copyright © 2022. StatPearls Publishing LLC; 2022.
    1. Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3-23. doi:10.1007/s12028-012-9695-z
    1. Kapur J, Elm J, Chamberlain JM, et al. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med. 2019;381(22):2103-2113. doi:10.1056/NEJMoa1905795
    1. Keppra injection for intravenous use. Package insert. UCB Pharmaceuticals Inc; 2020.
    1. Wheless JW, Clarke D, Hovinga CA, et al. Rapid infusion of a loading dose of intravenous levetiracetam with minimal dilution: a safety study. J Child Neurol. 2009;24(8):946-951. doi:10.1177/0883073808331351

LinkOut - more resources